Fractyl Health advances Revita pivotal obesity study
Fractyl Health, Inc. reported completion of participant randomization in REMAIN-1’s pivotal cohort, a randomized, double-blind, sham-controlled study of its Revita® endoscopic procedure for maintaining weight after GLP-1 therapy discontinuation.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Fractyl Health, Inc. reported completion of participant randomization in REMAIN-1’s pivotal cohort, a randomized, double-blind, sham-controlled study of its Revita® endoscopic procedure for maintaining weight after GLP-1 therapy discontinuation. This marks a key step toward generating definitive clinical evidence in adults with obesity who previously lost at least 15% of body weight on tirzepatide.
The company expects topline 6‑month pivotal data in early Q4 2026 and is targeting a potential U.S. FDA marketing application submission in late Q4 2026, informed by anticipated Q2 2026 FDA feedback on possible De Novo pathway use. Fractyl also reiterated its cash runway guidance into early 2027, positioning it to fund operations through planned 2026 clinical and regulatory milestones for Revita.
Insights
Fractyl advances Revita to pivotal stage with clear 2026 data and filing goals.
Fractyl Health has completed randomization in the REMAIN-1 Pivotal Cohort, a double-blind, sham-controlled trial testing Revita for weight maintenance after GLP-1 discontinuation. The study targets adults with obesity who achieved at least 15% total body weight loss on tirzepatide, aiming to address weight regain after stopping GLP-1 drugs.
The trial’s co-primary endpoints are percent total body weight regain at 6 months and the proportion of participants maintaining at least 5% total body weight loss at 12 months. A scheduled sequence of milestones in Q2 2026, Q3 2026, and early and late Q4 2026 outlines planned readouts and a potential FDA marketing application submission, with De Novo pathway feedback expected in Q2 2026.
The company reiterates a cash runway into early 2027, indicating resources to reach these 2026 data and regulatory events. Actual impact will depend on the strength of upcoming REVEAL-1, REMAIN-1 Midpoint, and REMAIN-1 pivotal results, along with final FDA feedback on pathway and submission timing.
8-K Event Classification
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Fractyl Health (GUTS) announce about the REMAIN-1 Pivotal Cohort?
When is Fractyl Health expecting pivotal Revita data from REMAIN-1?
What regulatory milestones did Fractyl Health outline for Revita in 2026?
How long is Fractyl Health’s cash runway according to this update?
What patient population is targeted in Fractyl Health’s REMAIN-1 Pivotal Cohort?
What is Revita and how is it positioned in Fractyl Health’s pipeline?
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): |
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction |
(Commission File Number) |
(IRS Employer |
||
|
|
|
|
|
|
||||
|
||||
(Address of Principal Executive Offices) |
|
(Zip Code) |
||
Registrant’s Telephone Number, Including Area Code: |
|
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
|
|
Trading |
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 7.01 Regulation FD Disclosure.
On February 26, 2026, Fractyl Health, Inc. (the “Company” or “Fractyl”) issued a press release announcing completion of participant randomization in its REMAIN-1 Pivotal Cohort, a randomized, double-blind, sham-controlled study evaluating Revita® for weight maintenance following GLP-1 therapy discontinuation, as well as updated guidance on 2026 Revita clinical and regulatory milestones and reiterated cash guidance. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
The information contained in Item 7.01 of this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be deemed incorporated by reference into any of the Company’s filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such filing
Item 9.01 Financial Statements and Exhibits.
Exhibit No |
Description |
99.1 |
Press Release dated February 26, 2026 |
104 |
Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
Fractyl Health, Inc. |
|
|
|
|
Date: |
February 26, 2026 |
By: |
/s/ Harith Rajagopalan |
|
|
|
Harith Rajagopalan, M.D., Ph.D., |
Exhibit 99.1
Fractyl Health Completes Randomization in REMAIN-1 Pivotal Cohort of Revita® for Post-GLP-1 Weight Maintenance
Topline 6-month pivotal data expected in early Q4 2026 with potential FDA marketing application submission expected in late Q4 2026
Company reiterates cash runway guidance into early 2027, beyond anticipated pivotal data readout
BURLINGTON, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) – Fractyl Health, Inc. (Nasdaq: GUTS) (the Company or Fractyl), a clinical stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes, today announced completion of participant randomization in its REMAIN-1 Pivotal Cohort, a double-blind, sham-controlled study evaluating Revita® for weight maintenance following GLP-1 therapy discontinuation.
“Completion of randomization in the REMAIN-1 Pivotal Cohort marks an important milestone as we advance Revita toward the definitive clinical evidence we believe will clearly establish its role in post-GLP-1 weight maintenance,” said Harith Rajagopalan, M.D., Ph.D., Co-Founder and Chief Executive Officer of Fractyl Health. “This study was prospectively designed and statistically powered to demonstrate Revita’s effect. The clinical insights from our REVEAL-1 and REMAIN-1 Midpoint Cohorts, as well as ongoing follow-up from our Germany Real-World Registry study, informed both the study design and our confidence in this program. With randomization now complete and our balance sheet positioned to support us through and beyond the pivotal readout, our focus is on disciplined execution as we prepare to report topline 6-month results in early Q4 2026. We are grateful to the participants, investigators, and clinical site teams whose commitment has made this progress possible.”
Pivotal Study Designed to Deliver Definitive Evidence
The REMAIN-1 Pivotal Cohort is a randomized, double-blind, sham-controlled study evaluating Revita in adults with obesity (BMI ≥30 kg/m2 and ≤45 kg/m2) who achieved ≥15% total body weight loss on tirzepatide. Following GLP-1 discontinuation, participants were randomized 2:1 to receive Revita or a sham endoscopic procedure. The co-primary endpoints are percent total body weight regain (Revita vs sham) at 6 months, and proportion of participants maintaining ≥5% total body weight loss at 12 months (responder rate). All participants receive standardized diet and lifestyle counseling throughout the study.
“The level of patient interest we experienced at Baylor was remarkable. We ultimately trained three endoscopists and installed two consoles to perform the Revita procedure to meet demand during the study,” said Mohammed Othman, M.D., Professor of Medicine, Baylor College of Medicine, and a REMAIN-1 Investigator. “Weight regain after GLP-1 discontinuation is a challenge I see regularly in clinical practice, and the enthusiasm from both patients and referring physicians throughout this trial reflects a real and urgent unmet need.”
2026 Revita Clinical and Regulatory Milestones
Fractyl is advancing toward multiple anticipated clinical and regulatory milestones across its REMAIN-1 weight maintenance program, supporting a clear and sequential path toward pivotal readout and potential U.S. regulatory submission:
The Company reiterates its previously announced cash runway into early 2027, making it well-positioned to fund operations through key 2026 clinical and regulatory milestones, including the Revita pivotal readout.
About Fractyl Health
Fractyl Health is a clinical stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes. The Company’s approach targets organ-level dysfunction to enable durable metabolic control without the burden of chronic therapy. Fractyl is headquartered in Burlington, Massachusetts.
About Revita®
Revita is Fractyl Health’s lead product candidate, designed to remodel the duodenal lining via a one-time, minimally invasive endoscopic procedure intended to restore healthy nutrient sensing and signaling disrupted by chronic metabolic disease. Revita has received FDA Breakthrough Device designation for weight maintenance in people with obesity who discontinue GLP-1 therapies. Revita is for investigational use only in the United States and is CE marked in the European Union and United Kingdom.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact are forward-looking statements. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will” and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward- looking statements contain these words. Forward-looking statements in this press release include, without limitation, statements regarding: our anticipated financial performance, including cash and cash equivalents, our expected cash runway, the promise and potential impact of our product candidates, including Revita’s potential for preserving weight loss after GLP-1 drug discontinuation; the design, initiation, timing and results of clinical enrollment and any clinical studies or readouts, including readouts from the REVEAL-1 Cohort, the REMAIN-1 Midpoint Cohort and the REMAIN-1 Pivotal Cohort; the potential treatment population or benefits for any of our product candidates or products; our regulatory strategy, including potential use and benefits of the De Novo pathway; our strategic and product development objectives and goals, including with respect to enabling long-term weight maintenance following GLP-1 therapy discontinuation; and the timing of any of the foregoing. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2024 and Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, filed with the Securities and Exchange Commission on November 12, 2025 and in our other filings with the SEC. These forward-looking statements are based on management’s current estimates and expectations. While the Company may elect to update such forward-looking statements at some point in the future, the Company disclaims any obligation to do so, even if subsequent events cause its views to change.
Contact
Brian Luque, Head of Investor Relations and Corporate Development
IR@fractyl.com, 951.206.1200